Leukemia Research
Volume 29, Issue 6 , Pages 641-647 , June 2005

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes

  • Rosangela Invernizzi

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0382 502160; fax: +39 0382 526223.
    • ,
  • Erica Travaglino

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Mara De Amici

      Affiliations

    • Department of Pediatrics, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Silvia Brugnatelli

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Isabella Ramajoli

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Bianca Rovati

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Chiara Benatti

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
    • ,
  • Edoardo Ascari

      Affiliations

    • Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy

,Accepted 26 November 2004.

References 

  1. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398–1401
  2. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  3. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000;111:43–51
  4. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958–965
  5. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881–894
  6. Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87:884–886
  7. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1–6
  8. Strupp C, Hildebrandt B, Germing U, Haas R, Gattermann N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia. 2003;17:1200–1202
  9. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program). 2003;176–199
  10. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004;28:325–332
  11. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  12. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427–1434
  13. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002;118:151–156
  14. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996;81:219–223
  15. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–1892
  16. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1999;91:4082–4085
  17. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  18. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22:424–431
  19. Steins MB, Padrò T, Bieker R, Ruiz S, Kropff M, Kienast J. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood. 2002;99:834–839
  20. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003;123:436–441
  21. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol. 1999;43:109–114
  22. Invernizzi R. The role of apoptosis in myelodysplastic syndrome. Haematologica. 2002;87:337–339
  23. Melenhorst JJ, Eniafe R, Follmann R, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol. 2002;119:97–105
  24. Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and surrogate angiogenesis markers. Ann Oncol. 2001;12:987–990
  25. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 1999;105:402–411

PII: S0145-2126(04)00393-5

doi: 10.1016/j.leukres.2004.11.008

Leukemia Research
Volume 29, Issue 6 , Pages 641-647 , June 2005

Article Tools

* Image Usage & Resolution